What the NAD+ literature shows — and where it stops.

Start here

NAD+ does two things. As a redox coenzyme (redox = chemistry that shuttles electrons to release energy), it ferries electrons through the reactions that turn food into ATP. As a signaling substrate, it is used up by maintenance enzymes — sirtuins, PARPs and CD38 — that repair DNA and tune metabolism. The strongest human evidence is simple: oral precursors raise blood NAD+ in a dose-dependent way. The weaker evidence is everything downstream — whether that rise changes how people age or feel. This page keeps those two tiers apart, and keeps NAD+ the coenzyme separate from NMN and NR, the precursors.

Mechanism: a coenzyme that is also a consumed substrate

NAD+ sits at the center of catabolism. It accepts electrons during glycolysis and the TCA cycle to become NADH, then NADH donates them to the mitochondrial electron transport chain to drive ATP synthesis — the NAD+↔NADH redox couple is the cell's electron currency. A foundational Endocrine Reviews article frames NAD+ as the direct link between a cell's redox state and its signaling, acting through NAD+-dependent deacetylases, poly(ADP-ribose) polymerases and transcription factors ^[9].

The second role is what makes NAD+ interesting beyond bioenergetics: it is a consumed cosubstrate. Sirtuins cleave NAD+ each time they deacylate a protein; PARP1 consumes large quantities during DNA-damage repair; and CD38, an NAD glycohydrolase, hydrolyzes NAD+ to generate the second messenger cADPR — thereby limiting how much NAD+ is left for PARPs and sirtuins ^[11]. Because all of these enzymes draw from one pool, NAD+ availability is a shared, competitive resource ^[5]. Mitochondrial supply matters too: in mice, the hepatocyte mitochondrial NAD+ transporter SLC25A47 used NAD+ to sustain SIRT3 and AMPKα activity, and deleting it raised liver lipid, triglyceride and cholesterol content and promoted tumorigenesis ^[13].

Three ways the body builds NAD+

There is no single NAD+ factory; the cell runs three converging routes, conserved from bacteria to humans ^[10]. The salvage pathway is dominant in mammals: it recycles nicotinamide back into NAD+ via NMN, with NAMPT (nicotinamide phosphoribosyltransferase) as the rate-limiting enzyme that sets the refill speed ^[10]. The Preiss-Handler pathway builds NAD+ from nicotinic acid (niacin), a distinct entry point. And de novo synthesis starts from the amino acid L-tryptophan through the kynurenine route ^[10]. Oral precursors plug into these routes at different points — NR feeds in through the NRK kinases, NMN one step below that, niacin through Preiss-Handler — which is why "a precursor" is not one thing but several molecules entering one shared synthesis network ^[10][9]. This is the biochemical reason the supplement aisle is full of precursors rather than NAD+ itself: you raise the pool by feeding the factory, not by swallowing the finished product, which is largely degraded before uptake ^[12].

Nicotinamide riboside (NR): the most-studied oral NAD+ precursor

Nicotinamide riboside is the most clinically characterized oral NAD+ booster. It enters NAD+ synthesis by a dedicated route — NR is phosphorylated to NMN by the NRK1/NRK2 kinases, then converted to NAD+ — bypassing the rate-limiting salvage step ^[10]. The defining human pharmacodynamic result comes from a randomized, double-blind, placebo-controlled trial in healthy overweight adults: across eight weeks, NR raised whole-blood NAD+ by 22%, 51% and 142% at 100, 300 and 1000 mg/day, and the elevation was maintained throughout the study ^[4]. The same trial found NR did not elevate LDL cholesterol or disrupt one-carbon metabolism, and produced no flushing — addressing two specific worries about high-dose B3-family intake and establishing NR as a well-tolerated, dose-scalable way to raise the NAD+ pool ^[4]. The dose-response is the headline: the blood-NAD+ rise scaled cleanly with the administered dose, which is the cleanest demonstration in the human literature that an oral precursor reaches the NAD+ pool in a predictable, graded way ^[4].

Nicotinamide mononucleotide (NMN): one step from NAD+

NMN sits one biochemical step from NAD+ — NMN is converted directly to NAD+ by the NMNAT enzymes. Two human randomized trials anchor its record. In prediabetic, postmenopausal women, 250 mg/day of oral NMN for 10 weeks significantly increased muscle insulin sensitivity on a hyperinsulinemic-euglycemic clamp and remodeled muscle insulin signaling, without changing body composition or HbA1c ^[1]. In a separate multicenter, double-blind, placebo-controlled, dose-ranging trial in healthy middle-aged adults, NMN at 300, 600 or 900 mg/day for 60 days raised blood NAD+ at days 30 and 60 across all groups versus placebo (p≤0.001), improved walking distance, and showed no safety issues at any dose, with 600 mg/day identified as the optimal dose ^[3].

NAD+ vs NMN: the coenzyme versus its precursor

NAD+ vs NMN is not a contest between two interchangeable products — it is the difference between a coenzyme and one of its building blocks. NAD+ is the active dinucleotide that enzymes use and consume. NMN is a precursor the body converts into NAD+ ^[10]. The practical consequence is delivery: intact oral NAD+ is poorly absorbed and largely degraded extracellularly before uptake ^[12], whereas oral NMN is absorbed and reliably raises whole-blood NAD+ over weeks of dosing ^[3]. So when a study reports that "NAD+ went up," check what was actually administered — in nearly all controlled human work it was a precursor, NMN or NR, not NAD+ itself. This site never describes an oral-NMN or oral-NR trial as "taking NAD+."

The senescence and circadian context

NAD+ metabolism is wired into how cells age and how they keep time, and the picture is not uniformly "more is better." NAMPT — the rate-limiting salvage enzyme — governs the proinflammatory senescence-associated secretory phenotype (SASP) independently of the growth-arrest part of senescence, working through an HMGA–NAMPT–NAD+ axis that ultimately activates NF-κB; the authors caution that NAD+ augmentation should be applied with precision in aging populations ^[6]. NAMPT-driven NAD+ synthesis also controls circadian metabolism tissue by tissue: in mice, NAMPT deletion lost 89% of circadian transcripts in brown fat and 77% in white fat, while skeletal muscle was completely refractory despite an equivalent NAD+ drop ^[7]. The lesson is that NAD+'s effects are context- and tissue-specific, not a single global dial.

Tolerability and adverse events in the studies

In the controlled oral-precursor trials, tolerability was good. NR at 100–1000 mg/day for 8 weeks produced no significant adverse-event difference from placebo at any dose and no flushing ^[4]; NMN at 250 mg/day for 10 weeks ^[1] and at 300–900 mg/day for 60 days ^[3] reported no serious adverse events. The documented downsides sit on the injectable side, not the oral side. IV NAD+ infusions can cause chest or abdominal discomfort, flushing and nausea if run too fast, and a pilot study showed infused NAD+ is rapidly and extensively metabolized — near-complete plasma removal within roughly the first two hours [12 context applies separately; see /dosage]. Critically, a compounded injectable NAD+ product was subject to an FDA Class I recall for elevated bacterial endotoxin — a documented quality risk specific to compounded injectables, not an approved treatment.

What the field still does not know

Raising blood NAD+ is well demonstrated; translating that rise into hard clinical outcomes is not. A 2025 narrative review of the human clinical evidence on NAD+ precursor supplementation in aging concluded that trials have shown limited efficacy, that age-related NAD+ decline has been observed consistently in only a limited number of human studies, and that data on tissue-specific NAD+ dynamics remain sparse — arguing for more human studies rather than extrapolation from rodents ^[14]. Much of the strongest anti-aging data still comes from mice ^[5]. And a context-dependent caution applies: because NAD+ supports proliferating cells, its role in oncology is dual, so the literature advises care in cancer populations. This digest reports those limits as plainly as it reports the positive findings.